Piramal Pharma Ltd
NSE:PPLPHARMA
Piramal Pharma Ltd
Other Equity
Piramal Pharma Ltd
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Piramal Pharma Ltd
NSE:PPLPHARMA
|
Other Equity
₹4.6B
|
CAGR 3-Years
-47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Other Equity
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Other Equity
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Other Equity
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Other Equity
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Other Equity
₹100.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Piramal Pharma Ltd
Glance View
Piramal Pharma Ltd. has embarked on a remarkable journey that reflects the dynamic world of pharmaceuticals and healthcare. Emerging from the rich tapestry of the Piramal Group's diverse business ventures, it has carved out a distinctive place for itself in the global pharmaceutical landscape. The company primarily navigates through three major streams: Contract Development and Manufacturing Organization (CDMO), Critical Care, and Consumer Products. Its CDMO division is the backbone, providing end-to-end solutions spanning the entire drug lifecycle, from development through to commercial manufacturing. By offering tailored solutions to pharmaceutical companies globally, Piramal Pharma not only strengthens its revenue streams but also builds lasting partnerships with some of the world’s leading pharmaceutical innovators. Beyond the realm of CDMO, Piramal Pharma's Critical Care segment specializes in catering to the acute care sector, dealing especially with inhalation anesthesia and pain management solutions. This division operates globally, emphasizing a diligent supply chain that ensures these life-sustaining products reach hospitals and clinics around the world. Meanwhile, its Consumer Products business makes a concerted effort to touch lives in a different manner—through over-the-counter health solutions that meet everyday health concerns of countless individuals. Operating at this unique intersection where science meets humanity, Piramal Pharma not only thrives through product sales but also invests heavily in R&D, seeking out innovative ways to address evolving market needs and inch its way forward in the competitive pharmaceutical arena.
See Also
What is Piramal Pharma Ltd's Other Equity?
Other Equity
4.6B
INR
Based on the financial report for Mar 31, 2024, Piramal Pharma Ltd's Other Equity amounts to 4.6B INR.
What is Piramal Pharma Ltd's Other Equity growth rate?
Other Equity CAGR 3Y
-47%
Over the last year, the Other Equity growth was 15%. The average annual Other Equity growth rates for Piramal Pharma Ltd have been -47% over the past three years .
You don't have any saved screeners yet